Abstract: The present disclosure relates to small molecule or polymer conjugated MetAP2 inhibitors. The present disclosure also relates to methods of treating, or ameliorating at least one symptom of metabolic dysfunction associated with a treatment in a subject having a disease, such as cancer. The present disclosure also relates to methods of treating, or ameliorating at least one symptom of cancer comprising administering a combination of a polymer conjugated MetAP2 inhibitors and at least one second agent wherein the second agent may induce metabolic dysfunction.

Abstract: The present disclosure relates to the technical field of organic photoelectric materials, in particular to an organic compound, an electronic component containing the organic compound, and an electronic device. The compound has a structure as shown by chemical formula 1?, wherein one of R1 to R4 is aa, and the other three are selected from substituents such as an alkyl, halogen and cyano; one of R5 to R8 is bb, and the other three are selected from substituents such as an alkyl, halogen and cyano; Y and Y1 are each independently cc; and L and L1 are a single bond, aryl, heteroaryl, etc. By using the organic compound of the present disclosure in an organic component, the driving voltage, luminous efficiency and lifespan of the organic component can be improved.

Abstract: A composition formed of a mixture of two compounds having similar thermal evaporation properties that are pre-mixed into an evaporation source that can be used to co-evaporate the two compounds into an emission layer in OLEDs via vacuum thermal evaporation process is disclosed.

Abstract: The present application discloses methods for the efficient preparation of high purity compounds of the Formula I, and their methods of use.

Abstract: The invention relates to processes for preparing isoindolin-1-one derivatives, and in particular processes for preparing (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The invention also relates to crystalline forms of the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid and its salts.

Abstract: An organic molecule is disclosed comprising: a first chemical moiety with a structure of formula I, and two second chemical moieties, each independently from another with a structure of formula II, wherein the first chemical moiety is linked to each of the two second chemical moieties via a single bond.

Abstract: This invention relates to photoswitchable inhibitors of histone deacetylases and methods of using the same.

Abstract: This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.

Abstract: The present invention relates to a complex of formula (II) constituted of at least 90% of a diastereoisomeric excess comprising a mixture of isomers II-RRR and II-SSS of formulae: The present invention also relates to a process for preparing and purifying said complex of formula (II), and also to a composition comprising said complex.

Abstract: The present invention provides a pharmaceutical combination comprising the EP4 antagonist of Formula (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl)-benzoic acid or a pharmaceutically acceptable salt thereof and at least one immune checkpoint inhibitor, preferably the sodium salt of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl) benzoic acid. A polymorphic form A of sodium salt of (R)-4-(1-(6-(4-(trifluoromethyl) benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl)benzoate characterized by a powder XRD spectrum with peaks at values of the angle 2?+0.2° of 4.3, 5.0, 5.8, 6.4, 7.1, 8.3, 8.7, 12.8, 15.3, 15.9 is also described. The combination and the polymorphic form A are described for use in the treatment of tumours.

Abstract: The present subject matter is directed to a luminogen exhibiting aggregation induced emission, wherein T1, T2, and T3 comprise one or more polyynes as a conjugated bridge. The present subject matter is also directed to an AIEgen comprising a hydrophilic pyridium group as a strong electron-withdrawing group; a piperazine group as an electron-donating group; and a ?-Cyanostilbene; wherein the AIEgen exhibits aggregation induced emission. The present subject matter is directed to a method of synthesizing an AIEgen and is further directed to a method of labeling comprising incubating a subject having cells with a conjugate formed by conjugating an AIEgen with an antibody; and selectively labeling desired cells by turn-on imaging, wherein labeling occurs when the desired cells are selectively stained by fluorescent emission of the AIEgen upon degradation of the antibody after cellular internalization of the conjugate through endocytosis.

Abstract: The invention relates to crystalline forms of the bis-HCl salt of a compound represented by Structural Formula 1, and pharmaceutical compositions comprising crystalline forms of the bis-HCL salt of a compound represented by Structural Formula 1 described herein. The crystalline forms of the bis-HCl salt of a compound of Structural Formula 1 and compositions comprising the crystalline forms of the compound of Structural Formula 1 provided herein, in particular, crystalline Form I, crystalline Form J, crystalline Form A, and crystalline Form B, or mixtures thereof, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders. Also described herein are methods for preparing the crystalline forms (e.g., Forms I, J, B and A) of the bis-HCl salt of a compound represented by Structural Formula 1.

Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

Abstract: The silyl phosphine compound of the present invention is represented by the formula (1) and has an arsenic content of not more than 1 ppm. The process for producing a silyl phosphine compound of the present invention is a process comprising mixing a basic compound, a silylating agent and phosphine to obtain a solution containing a silyl phosphine compound, removing a solvent from the solution to obtain a concentrated solution of a silyl phosphine compound, and distilling the concentrated solution, wherein an arsenic content in the phosphine is adjusted to not more than 1 ppm by volume in terms of arsine. The process for producing InP quantum dots of the present invention uses, as a phosphorus source, a silyl phosphine compound represented by the formula (1) and having an arsenic content of not more than 1 ppm by mass. (For definition of R, see the specification.

Abstract: A compound represented by formula I or II. X represents a mono substituent on a benzene ring, and is selected from —H, —I, —Br, —Cl, —F, —CN, an amino, and a derivative thereof; R1 is a C2-10 alkyl, C2-10 alkyl substituted by cyclopropane or fluorine, except n-butyl; and M is an amine ion or metal ion.

Abstract: The disclosure relates generally novel sulfur containing glycerol mono-ester derivatives and methods useful for treating gram positive, gram negative, fungal and envelope viral infections in a patient.

Abstract: A method of preparing a 2,6 disubstituted anilines includes, reacting a 2-amino isophthalic acid diester with sufficient Grignard reagent R2CH2MgX to form the corresponding diol product, dehydrating the diol product to the corresponding dialkene; and hydrogenating the diol product to form the corresponding aniline. The 2,6 disubstituted anilines can be used to produce N-Heterocyclic Carbenes (NHCs). The NHCs can find application in various fields such as organic synthesis, catalysis and macromolecular chemistry. Palladium catalysts containing the NHCs are also described.

Abstract: The problem addressed by this invention is to achieve a useful and novel method for producing dicyanocyclohexane and bis(aminomethyl)cyclohexane. This problem was solved by providing a method for producing dicyanocyclohexane having a cyanation step in which dicyanocyclohexane is obtained by a cyanation reaction of cyanocyclohexane-1-carboxylic acid and/or a salt thereof with an ammonia source, and a method for producing bis(aminomethyl)cyclohexane using the dicyanocyclohexane thus produced.

Abstract: The presently-disclosed subject matter describes distorted gold (I) phosphine compounds. The presently-disclosed subject matter also describes a method for killing fungus comprising contacting fungus with distorted gold (I) phosphine compounds. The presently-disclosed subject matter further describes a method of preventing or disrupting a biofilm on a surface comprising contacting a surface with distorted gold (I) phosphine compounds.

Abstract: The invention provides a facile process for preparing various Group VI precursor compounds, set forth below as Formula (I), useful in the vapor deposition of certain Group VI metals onto solid substrates, especially microelectronic semiconductor device substrates. Also provided is a process for the preparation of such precursor compounds. Additionally, the invention provides a method for vapor deposition of Group VI metals onto microelectronic device substrates utilizing the precursor compounds of the invention.